Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
    • Institutional and Non-member
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook

Explore JNM’s collection of the most influential or frequently cited manuscripts in its 60-year history.

  • Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition
  • Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive Evaluation of Aggressiveness: Comparison with Gleason Score in a Prospective Phase 2 Clinical Trial
  • JNM Impact Factor 7.887
    The Journal of Nuclear Medicine has achieved the highest impact factor ever in its 60-year history, ranking fourth among all medical journals worldwide.
  • 1
  • 2
  • 3

Published Ahead of Print

  • You have access
    Accuracy of 18F-fluorocholine PET for the detection of parathyroid adenomas: prospective single center study
    Thomas A. Hope, Claire Graces, Jeremie Calais, Eric Ehman, Geoffrey Bates Johnson, Daniel Thompson, Maya Aslam, Quan-Yang Duh, Jessica Gosnell, Wen Shen, Sanziana Roman, Julie A. Sosa, Wouter Kluijfhout, Carolyn S. Seib, Javier Villanueva-Meyer, Miguel Hernandez Pampaloni and Insoo Suh
    Journal of Nuclear Medicine March 5, 2021, jnumed.120.256735; DOI: https://doi.org/10.2967/jnumed.120.256735
  • You have access
    Repurposing 99mTc-1 mebrofenin as a probe for molecular imaging of hepatocyte 2 transporters
    Solene Marie, Irene HERNANDEZ-LOZANO, Oliver Langer and Nicolas Tournier
    Journal of Nuclear Medicine March 5, 2021, jnumed.120.261321; DOI: https://doi.org/10.2967/jnumed.120.261321
  • You have access
    PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer
    Lucia Baratto, Hong Song, Heying Duan, Negin Hatami, Hilary Bagshaw, Mark Buyyounouski, Steven Hancock, Sumit Anil Shah, Sandy Srinivas, Patrick Swift, Farshad Moradi, Guido A Davidzon and Andrei Iagaru
    Journal of Nuclear Medicine March 5, 2021, jnumed.120.259630; DOI: https://doi.org/10.2967/jnumed.120.259630
  • You have access
    Interobserver agreement in automated metabolic tumor volume measurements of Deauville score 4 and 5 lesions at interim 18F-FDG PET in DLBCL
    Gerben JC Zwezerijnen, Jakoba J Eertink, Coreline N Burggraaff, Sanne E Wiegers, Ekhlas A Shaban, Simone Pieplenbosch, Daniela E Oprea-Lager, Pieternella J Lugtenburg, Otto S Hoekstra, Henrica CW de Vet, Josee M Zijlstra and Ronald Boellaard
    Journal of Nuclear Medicine March 5, 2021, jnumed.120.258673; DOI: https://doi.org/10.2967/jnumed.120.258673
  • You have access
    Reply: From mice to men: the exocrine pancreas does not matter for human GLP-1 receptor imaging
    Greg M. Thurber
    Journal of Nuclear Medicine March 5, 2021, jnumed.121.262029; DOI: https://doi.org/10.2967/jnumed.121.262029
  • You have access
    First-in-human study of novel SSTR antagonist 177Lu-DOTA-LM3 for peptide receptor radionuclide therapy in patients with metastatic neuroendocrine neoplasms: dosimetry, safety and efficacy
    Richard P. Baum, Jingjing Zhang, Christiane Schuchardt, Dirk Mueller and Helmut Maecke
    Journal of Nuclear Medicine March 5, 2021, jnumed.120.258889; DOI: https://doi.org/10.2967/jnumed.120.258889
View more published ahead of print articles

Featured Articles

  • Advances in Receptor-Targeted Radiolabeled Peptides for Melanoma Imaging and Therapy
    February 23, 2021
  • Phantom Preparation Using a Dilution Technique
    February 23, 2021
  • FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology?
    February 23, 2021
  • A Conversation Between Hong Wu and Johannes Czernin
    February 23, 2021
  • Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase...
    February 23, 2021
  • Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive...
    February 23, 2021

About The Journal of Nuclear Medicine

The Journal of Nuclear Medicine (JNM)—self-published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), a nonprofit, international scientific and professional organization—offers readers around the globe clinical investigations, basic science reports, continuing education articles, book reviews, employment opportunities, and updates on rapidly changing issues in practice and research.

Current issue

Journal of Nuclear Medicine: 62 (3)
Journal of Nuclear Medicine
Vol. 62, Issue 3
March 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author

Issue highlights

  • Multimodal Imaging of 2-Cycle PRRT with 177Lu-DOTA-JR11 and 177Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model
  • Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive Evaluation of Aggressiveness: Comparison with Gleason Score in a Prospective Phase 2 Clinical Trial
  • Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition
  • Most Cited
  • Most Read
Loading
  • 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
  • Deep Learning Analysis of Upright-Supine High-Efficiency SPECT Myocardial Perfusion Imaging for Prediction of Obstructive Coronary Artery Disease: A Multicenter Study
  • Incidental Findings Suggestive of COVID-19 in Asymptomatic Patients Undergoing Nuclear Medicine Procedures in a High-Prevalence Region
  • Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
  • Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention
More...
Back to top
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire